Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/37123
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marcellin, P. | - |
dc.contributor.author | De Bony, F. | - |
dc.contributor.author | Garret, C. | - |
dc.contributor.author | Altman, C. | - |
dc.contributor.author | Boige, V. | - |
dc.contributor.author | Castelnau, C. | - |
dc.contributor.author | Laurent-Puig, P. | - |
dc.contributor.author | Trinchet, J. | - |
dc.contributor.author | Rolan, P. | - |
dc.contributor.author | Chen, C. | - |
dc.contributor.author | Mamet, J. | - |
dc.contributor.author | Bidault, R. | - |
dc.date.issued | 2001 | - |
dc.identifier.citation | British Journal of Clinical Pharmacology, 2001; 51(5):410-414 | - |
dc.identifier.issn | 0306-5251 | - |
dc.identifier.issn | 1365-2125 | - |
dc.identifier.uri | http://hdl.handle.net/2440/37123 | - |
dc.description.abstract | AIMS: Lamotrigine, an antiepileptic drug, is cleared from the systemic circulation mainly by glucuronidation. The possibility of changes in the pharmacokinetics of lamotrigine in plasma owing to hepatic dysfunction has been evaluated. METHODS: Thirty-six subjects, including 24 patients with various degrees of liver cirrhosis and 12 healthy volunteers received a single 100 mg dose of lamotrgine. Blood samples were taken for 7 days in all subjects, except nine with severe cirrhosis, who had a 29 day blood sampling period. RESULTS: The pharmacokinetics of lamotrigine were comparable between the patients with moderate cirrhosis (corresponding to Child-Pugh grade A) and the healthy subjects. Plasma oral clearance mean ratios (90% confidence interval) in patients with severe cirrhosis without or with ascites (corresponding, respectively, to Child-Pugh grade B and C) to healthy subjects were, respectively, 60% (44%, 83%) and 36% (25%, 52%). Plasma half-life mean ratios (90% confidence interval) in these two patient groups to healthy subjects were, respectively, 204% (149%, 278%) and 287% (202%, 408%). CONCLUSIONS: Lamotrigine administered as a single oral dose of 100 mg was well tolerated in all groups. Initial, escalation and maintenance doses should generally be reduced by approximately 50 or 75% in patients with Child-Pugh Grade B or C cirrhosis. Escalation and maintenance doses should be adjusted according to clinical response. | - |
dc.description.statementofresponsibility | P. Marcellin, F. De Bony, C. Garret, C. Altman, V. Boige, C. Castelnau, P. Laurent-Puig, J. C. Trinchet, P. Rolan, C. Chen, J. P. Mamet, R. Bidault | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.source.uri | http://dx.doi.org/10.1046/j.1365-2125.2001.01389.x | - |
dc.subject | Cirrhosis | - |
dc.subject | lamotrigine | - |
dc.subject | pharmacokinetics | - |
dc.title | Influence of cirrhosis on lamotrigine pharmacokinetics | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1046/j.1365-2125.2001.01389.x | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 6 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.